Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 2
1979 6
1980 12
1981 38
1982 49
1983 28
1984 37
1985 69
1986 94
1987 204
1988 315
1989 337
1990 331
1991 298
1992 286
1993 295
1994 263
1995 244
1996 244
1997 176
1998 140
1999 129
2000 134
2001 117
2002 120
2003 109
2004 98
2005 87
2006 68
2007 81
2008 85
2009 71
2010 59
2011 67
2012 72
2013 57
2014 71
2015 48
2016 59
2017 41
2018 45
2019 47
2020 50
2021 51
2022 27
2023 29
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

5,185 results

Results by year

Filters applied: . Clear all
Page 1
Interleukin-2 toxicity.
Siegel JP, Puri RK. Siegel JP, et al. J Clin Oncol. 1991 Apr;9(4):694-704. doi: 10.1200/JCO.1991.9.4.694. J Clin Oncol. 1991. PMID: 2066765 Review.
Therapeutic potential of interleukin-2 in autoimmune diseases.
Yuan Y, Kolios AGA, Liu Y, Zhang B, Li H, Tsokos GC, Zhang X. Yuan Y, et al. Trends Mol Med. 2022 Jul;28(7):596-612. doi: 10.1016/j.molmed.2022.04.010. Epub 2022 May 24. Trends Mol Med. 2022. PMID: 35624009 Review.
Interleukin 2.
Hamblin TJ. Hamblin TJ. BMJ. 1990 Feb 3;300(6720):275-6. doi: 10.1136/bmj.300.6720.275. BMJ. 1990. PMID: 2106954 Free PMC article. Review. No abstract available.
Interleukin-2 self-association.
Fleischmann JD, Wentworth D, Valencic F, Imbembo AL, Koehler KA. Fleischmann JD, et al. Biochem Biophys Res Commun. 1988 Apr 29;152(2):879-85. doi: 10.1016/s0006-291x(88)80121-9. Biochem Biophys Res Commun. 1988. PMID: 3259135
Recombinant interleukin-2.
Bruton JK, Koeller JM. Bruton JK, et al. Pharmacotherapy. 1994 Nov-Dec;14(6):635-56. Pharmacotherapy. 1994. PMID: 7885967 Review.
Clinical toxicity of interleukin-2.
Vial T, Descotes J. Vial T, et al. Drug Saf. 1992 Nov-Dec;7(6):417-33. doi: 10.2165/00002018-199207060-00004. Drug Saf. 1992. PMID: 1418698 Review.
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.
Solomon I, Amann M, Goubier A, Arce Vargas F, Zervas D, Qing C, Henry JY, Ghorani E, Akarca AU, Marafioti T, Śledzińska A, Werner Sunderland M, Franz Demane D, Clancy JR, Georgiou A, Salimu J, Merchiers P, Brown MA, Flury R, Eckmann J, Murgia C, Sam J, Jacobsen B, Marrer-Berger E, Boetsch C, Belli S, Leibrock L, Benz J, Koll H, Sutmuller R, Peggs KS, Quezada SA. Solomon I, et al. Nat Cancer. 2020 Dec;1(12):1153-1166. doi: 10.1038/s43018-020-00133-0. Epub 2020 Nov 9. Nat Cancer. 2020. PMID: 33644766 Free PMC article.
The interleukin-2 receptor.
Waldmann TA. Waldmann TA. J Biol Chem. 1991 Feb 15;266(5):2681-4. J Biol Chem. 1991. PMID: 1993646 Free article. Review. No abstract available.
[Interleukin-2 (IL-2)].
Taguchi T. Taguchi T. Gan To Kagaku Ryoho. 1994 Apr;21(5):719-24. Gan To Kagaku Ryoho. 1994. PMID: 8154900 Review. Japanese.
Managing toxicities of high-dose interleukin-2.
Schwartz RN, Stover L, Dutcher JP. Schwartz RN, et al. Oncology (Williston Park). 2002 Nov;16(11 Suppl 13):11-20. Oncology (Williston Park). 2002. PMID: 12469935 Free article. Review.
5,185 results